Anti-diabetic and hepato-renal protective effects of ziyuglycoside II methyl ester in type 2 diabetic mice

Nutrients

Volumn 7, Issue 7, 2015, Pages 5469-5483

  Son, Dong Ju ^a   Hwang, Seock Yeon ^b   Kim, Myung Hyun ^b   Park, Un Kyu ^b   Kim, Byoung Soo ^b  

^a Chungbuk National University   (South Korea)

^b Daejeon University   (South Korea)

Author keywords

Diabetes; Diabetic hepatopathy; Diabetic nephropathy; Sanguisorba officinalis; Ziyuglycoside

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C PEPTIDE; CREATININE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLANT MEDICINAL PRODUCT; UNCLASSIFIED DRUG; ZIYUGLYCOSIDE I; ZIYUGLYCOSIDE II METHYL ESTER; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; LIPID; SAPONIN; ZIYUGLYCOSIDE II;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; BLOOD BIOCHEMISTRY; CARBON NUCLEAR MAGNETIC RESONANCE; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; DOWN REGULATION; FOOD INTAKE; LIPID PEROXIDATION; LIVER PROTECTION; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; RADIOIMMUNOASSAY; RENAL PROTECTION; SANGUISORBA; SANGUISORBA OFFICINALIS; THIN LAYER CHROMATOGRAPHY; ANIMAL; BLOOD; CHEMICAL STRUCTURE; CHEMISTRY; GLUCOSE BLOOD LEVEL; METABOLISM; NONOBESE DIABETIC MOUSE;

MUS; SANGUISORBA OFFICINALIS;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HYPOGLYCEMIC AGENTS; INSULIN; LIPIDS; MALE; MICE; MICE, INBRED NOD; MOLECULAR STRUCTURE; SANGUISORBA; SAPONINS;

EID: 84936966841     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu7075232     Document Type: Article

References (50)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009, 32, S62–S67.
2. Triggle, C.R.; Ding, H. Cardiovascular impact of drugs used in the treatment of diabetes. Ther. Adv. Chronic Dis. 2014, 5, 245–268.
3. Warren, R.E. The stepwise approach to the management of type 2 diabetes. Diabetes Res. Clin. Pract. 2004, 65, S3–S8.
4. Ho, J.; Leung, A.K.; Rabi, D. Hypoglycemic agents in the management of type 2 diabetes mellitus. Recent Pat. Endocr. Metab. Immune Drug Discov. 2011, 5, 66–73.
5. Murray, M.T.; Lyon, M.R. How to Prevent and Treat Diabetes with Natural Medicine; Riverhead Books: New York, NY, USA, 2003; p. 369.
6. Fuhrman, J. The End of Diabetes: The Eat to Live Plan to Prevent and Reverse Diabetes, 1st ed.; HarperOne, an Imprint of HarperCollins Publishers: New York, NY, USA, 2013; p. 301.
7. Pasupuleti, V.K.; Anderson, J.W. Nutraceuticals, Glycemic Health and Type 2 Diabetes, 1st ed.; Wiley-Blackwell/IFT Press: Ames, IA, USA, 2008; Volume 17, p. 489.
8. Xiao, J.B.; Hogger, P. Dietary polyphenols and type 2 diabetes: Current insights and future perspectives. Curr. Med. Chem. 2015, 22, 23–38.
9. Habicht, S.D.; Ludwig, C.; Yang, R.Y.; Krawinkel, M.B. Momordica charantia and type 2 diabetes: From in vitro to human studies. Curr. Diabetes Rev. 2014, 10, 48–60.
10. Dembinska-Kiec, A.; Mykkanen, O.; Kiec-Wilk, B.; Mykkanen, H. Antioxidant phytochemicals against type 2 diabetes. Br. J. Nutr. 2008, 99, ES109–ES117.
11. Zhang, S.; Liu, X.; Zhang, Z.L.; He, L.; Wang, Z.; Wang, G.S. Isolation and identification of the phenolic compounds from the roots of sanguisorba officinalis l and their antioxidant activities. Molecules 2012, 17, 13917–13922.
12. Ravipati, A.S.; Zhang, L.; Koyyalamudi, S.R.; Jeong, S.C.; Reddy, N.; Bartlett, J.; Smith, P.T.; Shanmugam, K.; Munch, G.; Wu, M.J.; et al. Antioxidant and anti-inflammatory activities of selected chinese medicinal plants and their relation with antioxidant content. BMC Complement. Altern. Med. 2012, 12, 173.
13. Gao, X.; Wu, J.; Zou, W.; Dai, Y. Two ellagic acids isolated from roots of sanguisorba officinalis l promote hematopoietic progenitor cell proliferation and megakaryocyte differentiation. Molecules 2014, 19, 5448–5458.
14. Shin, J.A.; Kim, J.S.; Kwon, K.H.; Nam, J.S.; Jung, J.Y.; Cho, N.P.; Cho, S.D. Apoptotic effect of hot water extract of sanguisorba officinalis L. in human oral cancer cells. Oncol. Lett. 2012, 4, 489–494.
15. Choi, E.S.; Kim, J.S.; Kwon, K.H.; Kim, H.S.; Cho, N.P.; Cho, S.D. Methanol extract of sanguisorba officinalis l with cytotoxic activity against pc3 human prostate cancer cells. Mol. Med. Rep. 2012, 6, 670–674.
16. Liang, J.G.; Chen, J.P.; Tan, Z.W.; Peng, J.; Zheng, X.; Nishiura, K.; Ng, J.; Wang, Z.Y.; Wang, D.M.; Chen, Z.W.; et al. Extracts of the medicinal herb sanguisorba officinalis inhibit the entry of human immunodeficiency virus-1. J. Food Drug Anal. 2013, 21, S52–S58.
17. Liu, Y.; Nielsen, M.; Staerk, D.; Jager, A.K. High-resolution bacterial growth inhibition profiling combined with hplc-hrms-spe-nmr for identification of antibacterial constituents in chinese plants used to treat snakebites. J. Ethnopharmacol. 2014, 155, 1276–1283.
18. Zhang, L.; Koyyalamudi, S.R.; Jeong, S.C.; Reddy, N.; Smith, P.T.; Ananthan, R.; Longvah, T. Antioxidant and immunomodulatory activities of polysaccharides from the roots of sanguisorba officinalis. Int. J. Biol. Macromol. 2012, 51, 1057–1062.
19. Cai, Z.; Li, W.; Wang, H.; Yan, W.; Zhou, Y.; Wang, G.; Cui, J.; Wang, F. Anti-tumor and immunomodulating activities of a polysaccharide from the root of sanguisorba officinalis l. Int. J. Biol. Macromol. 2012, 51, 484–488.
20. Hu, J.; Song, Y.; Li, H.; Yang, B.; Mao, X.; Zhao, Y.; Shi, X. Cytotoxic triterpene glycosides from the roots of sanguisorba officinalis. Arch. Pharm. Res. 2014.
21. Tong, H.; Song, J.; Zhang, Z.; Mao, D.; Sun, G.; Jiang, G. Inhibitory function of p-selectin-mediated leukocyte adhesion by the polysaccharides from sanguisorba officinalis. Pharm. Biol. 2015, 53, 354–359.
22. Sun, W.; Zhang, Z.L.; Liu, X.; Zhang, S.; He, L.; Wang, Z.; Wang, G.S. Terpene glycosides from the roots of sanguisorba officinalis l. And their hemostatic activities. Molecules 2012, 17, 7629–7636.
23. Zhu, X.; Wang, K.; Zhang, K.; Zhu, L.; Zhou, F. Ziyuglycoside ii induces cell cycle arrest and apoptosis through activation of ros/jnk pathway in human breast cancer cells. Toxicol. Lett. 2014, 227, 65–73.
24. Zhu, X.; Wang, K.; Zhang, K.; Huang, B.; Zhang, J.; Zhang, Y.; Zhu, L.; Zhou, B.; Zhou, F. Ziyuglycoside ii inhibits the growth of human breast carcinoma mda-mb-435 cells via cell cycle arrest and induction of apoptosis through the mitochondria dependent pathway. Int. J. Mol. Sci. 2013, 14, 18041–18055.
25. Zhu, A.K.; Zhou, H.; Xia, J.Z.; Jin, H.C.; Wang, K.; Yan, J.; Zuo, J.B.; Zhu, X.; Shan, T. Ziyuglycoside ii-induced apoptosis in human gastric carcinoma bgc-823 cells by regulating bax/bcl-2 expression and activating caspase-3 pathway. Braz. J. Med. Biol. Res. 2013, 46, 670–675.
26. Mukherjee, P.K.; Maity, N.; Nema, N.K.; Sarkar, B.K. Bioactive compounds from natural resources against skin aging. Phytomedicine 2011, 19, 64–73.
27. Kim, Y.H.; Chung, C.B.; Kim, J.G.; Ko, K.I.; Park, S.H.; Kim, J.H.; Eom, S.Y.; Kim, Y.S.; Hwang, Y.I.; Kim, K.H. Anti-wrinkle activity of ziyuglycoside i isolated from a sanguisorba officinalis root extract and its application as a cosmeceutical ingredient. Biosci. Biotechnol. Biochem. 2008, 72, 303–311.
28. Liu, X.; Cui, Y.; Yu, Q.; Yu, B. Triterpenoids from sanguisorba officinalis. Phytochemistry 2005, 66, 1671–1679.
29. Choi, J.; Kim, M.Y.; Cha, B.C.; Yoo, E.S.; Yoon, K.; Lee, J.; Rho, H.S.; Kim, S.Y.; Cho, J.Y. Zym-201 sodium succinate ameliorates streptozotocin-induced hyperlipidemic conditions. Planta Med. 2012, 78, 12–17.
30. Choi, J.; Yu, T.; Cha, B.C.; Rhee, M.H.; Yoo, E.S.; Kim, M.Y.; Lee, J.; Cho, J.Y. Modulatory effects of zym-201 sodium succinate on dietary-induced hyperlipidemic conditions. Die Pharm. 2011, 66, 791–797.
31. Cho, J.Y.; Choi, J.; Park, J.G.; Yi, Y.S.; Hossen, M.J.; Kim, H.; Ro, J.; Cha, B.C.; Yoo, E.S.; Kim, J.H.; et al. Alcohol-induced hyperlipidemia is ameliorated by orally administered dwp208, a sodium succinate form of zym201. Korean J. Physiol. Pharmacol. 2014, 18, 469–474.
32. Lee, Y.E.; Kim, S.; Jung, W.J.; Lee, H.S.; Kim, M.Y. Immunomodulatory effects of zym-201 on lps-stimulated b cells. Immune Netw. 2014, 14, 260–264.
33. Cho, J.Y.; Yoo, E.S.; Cha, B.C.; Park, H.J.; Rhee, M.H.; Han, Y.N. The inhibitory effect of triterpenoid glycosides originating from sanguisorba officinalis on tissue factor activity and the production of tnf-alpha. Planta Med. 2006, 72, 1279–1284.
34. Sasmakov, S.A.; Putieva, Z.M.; Kachala, V.V.; Saatov, Z.; Shashkov, A.S. Triterpene glycosides of zygophyllum eichwaldii. Ii. Structure of zygoeichwaloside i. Chem. Nat. Compd. 2001, 37, 347–350.
35. Tze, W.J.; Thompson, K.H.; Leichter, J. Hbalc—An indicator of diabetic control. J. Pediatr. 1978, 93, 13–16.
36. Jamall, I.S.; Smith, J.C. Effects of cadmium on glutathione peroxidase, superoxide dismutase, and lipid peroxidation in the rat heart: A possible mechanism of cadmium cardiotoxicity. Toxicol. Appl. Pharmacol. 1985, 80, 33–42.
37. Orland, M.J.; Permutt, M.A. Quantitative analysis of pancreatic proinsulin mrna in genetically diabetic (db/db) mice. Diabetes 1987, 36, 341–347.
38. Ibrahim, M.M. Subcutaneous and visceral adipose tissue: Structural and functional differences. Obes. Rev. 2010, 11, 11–18.
39. Sader, S.; Nian, M.; Liu, P. Leptin: A novel link between obesity, diabetes, cardiovascular risk, and ventricular hypertrophy. Circulation 2003, 108, 644–646.
40. Jones, A.G.; Hattersley, A.T. The clinical utility of c-peptide measurement in the care of patients with diabetes. Diabet. Med. 2013, 30, 803–817.
41. Sanchez-Quesada, J.L.; Perez, A. Modified lipoproteins as biomarkers of cardiovascular risk in diabetes mellitus. Endocrinol. Y Nutr. 2013, 60, 518–528.
42. Kim, C.M.; Yi, S.J.; Cho, I.J.; Ku, S.K. Red-koji fermented red ginseng ameliorates high fat diet-induced metabolic disorders in mice. Nutrients 2013, 5, 4316–4332.
43. Hijmans, B.S.; Grefhorst, A.; Oosterveer, M.H.; Groen, A.K. Zonation of glucose and fatty acid metabolism in the liver: Mechanism and metabolic consequences. Biochimie 2014, 96, 121–129.
44. Tolman, K.G.; Fonseca, V.; Dalpiaz, A.; Tan, M.H. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 2007, 30, 734–743.
45. Torbenson, M.; Chen, Y.Y.; Brunt, E.; Cummings, O.W.; Gottfried, M.; Jakate, S.; Liu, Y.C.; Yeh, M.M.; Ferrell, L. Glycogenic hepatopathy: An underrecognized hepatic complication of diabetes mellitus. Am. J. Surg. Pathol. 2006, 30, 508–513.
46. Chan, G.C.; Tang, S.C. Diabetic nephropathy: Landmark clinical trials and tribulations. Nephrol. Dial. Transplant. 2015.
47. Garg, M.C.; Chaudhary, D.P.; Bansal, D.D. Effect of vitamin e supplementation on diabetes induced oxidative stress in experimental diabetes in rats. Indian J. Exp. Biol. 2005, 43, 177–180.
48. Ceriello, A.; Quatraro, A.; Giugliano, D. New insights on non-enzymatic glycosylation may lead to therapeutic approaches for the prevention of diabetic complications. Diabet. Med. 1992, 9, 297–299.
49. Mukherjee, B.; Mukherjee, J.R.; Chatterjee, M. Lipid peroxidation, glutathione levels and changes in glutathione-related enzyme activities in streptozotocin-induced diabetic rats. Immunol. Cell Biol. 1994, 72, 109–114.
50. Jung, U.J.; Park, Y.B.; Kim, S.R.; Choi, M.S. Supplementation of persimmon leaf ameliorates hyperglycemia, dyslipidemia and hepatic fat accumulation in type 2 diabetic mice. PLoS ONE 2012, 7, e49030.